Form 4: Upstream Bio Director Receives Equity Grant

Director Harold Edward Fleming was granted 17,096 stock options in Upstream Bio, Inc. to be held for the benefit of Enavate Sciences, LP.

Summary

• Director Harold Edward Fleming received a grant of 17,096 stock options on June 9, 2026.
• The options have an exercise price of $6.69 per share.
• The options vest in full on the earlier of June 9, 2027, or the date of the next Annual Meeting of Stockholders.
• The reporting person disclaims beneficial ownership, holding the securities for the benefit of Enavate Sciences, LP.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is subject to the director's continued service on the board.

Future Outlook

The options are set to vest in one year, contingent upon continued board service.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard practice in the biotechnology sector to incentivize board members and align their interests with institutional investors like Enavate Sciences, LP.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard director compensation packages for mid-cap biotechnology firms.

Corporate Governance

Related Party Transactions

• Director Harold Edward Fleming holds the granted securities for the benefit of Enavate Sciences, LP.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity incentive grant.

Next Steps

• Vesting of options on June 9, 2027, or the next Annual Meeting of Stockholders.

Key Dates

Keywords

Upstream Bio, UPB, Form 4, Director Compensation, Stock Options, Insider Transaction